Synergistic Combinations

Boswellia's combination value is one of its strongest oncology features.

Special report

With chemotherapy and radiotherapy

Common areas of interest include:

• cisplatin in NSCLC

• docetaxel resistance in prostate cancer

• taxane resistance in ovarian cancer

• radiosensitisation in glioblastoma and NSCLC

• protection against radiation-related cerebral oedema in brain tumour patients

With natural compounds

Common pairings include:

• Curcumin — complementary NF-κB and inflammatory-pathway inhibition

• Polydatin / resveratrol — broader pathway coverage in integrative neuro-oncology logic

• Piperine or Piper longum — bioavailability support

• Quercetin — complementary inflammatory and signalling effects

• Vitamin D3 — possible immune and differentiation overlap

Practical interpretation

The curcumin-plus-Boswellia combination is especially compelling because it deepens inflammatory-pathway coverage without relying on identical mechanism profiles.

Key References

AKBA suppresses docetaxel-resistant prostate cancer cells in vitro and in vivo by blocking Akt and STAT3 signaling
https://pmc.ncbi.nlm.nih.gov/articles/PMC6786291/

Enhanced Bioavailability of Boswellic Acid by Piper longum
https://pmc.ncbi.nlm.nih.gov/articles/PMC7770183/

New Approach for Enhancing Survival in Glioblastoma
https://pmc.ncbi.nlm.nih.gov/articles/PMC12293909/

Jump to another Boswellia page

Core pages

• Boswellia in Oncology Overview

• Evidence Summary

• Anticancer Mechanisms

• Boswellia Evidence by Cancer Type

Mechanism deep dives

• Redox Dual Action

• NRF2 Impact

• Ferroptosis Findings

• Immune Effects

Practical pages

• Pharmacokinetics & Metabolism

• Safety & Interactions

• Synergistic Combinations

• Hydroxychloroquine + Boswellia

• Dosing & Timing

• Sourcing Quality Boswellia

Cancer-type pages

• Glioblastoma & Brain Tumours

• Breast Cancer

• Colorectal Cancer

• Pancreatic Cancer

• Prostate Cancer

• Non-Small Cell Lung Cancer

• Ovarian Cancer

• Other Cancer Types